Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.58 |
| ▸ | CTSS | P25774 | 12/20 | 0.58 |
| ▸ | CTSB | P07858 | 12/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5685692 | 1.00 | CTSK (0.58) | CTSKCTSSCTSBCTSLTGFBR1 | |
| SCHEMBL1375968 | 0.88 | CTSK (0.59) | CTSKCTSSCTSBCTSL | |
| SCHEMBL4989195 | 0.84 | CTSB (0.54) | CTSKCTSSCTSBCTSL | |
| SCHEMBL4701312 | 0.82 | CTSK (0.58) | CTSKCTSSCTSBCTSLTGFBR1 | |
| SCHEMBL6207942 | 0.82 | CTSK (0.58) | CTSKCTSSCTSBCTSLTGFBR1 | |
| SCHEMBL4698976 | 0.81 | CTSK (0.56) | CTSKCTSSCTSBCTSLPTPN2 | |
| SCHEMBL4612749 | 0.80 | CTSK (0.53) | CTSKCTSSCTSBCTSLPTPN2 | |
| SCHEMBL4612755 | 0.80 | CTSK (0.58) | CTSKCTSSCTSBCTSL | |
| SCHEMBL4612752 | 0.80 | CTSK (0.58) | CTSKCTSSCTSBCTSL | |
| SCHEMBL4698794 | 0.79 | CTSK (0.53) | CTSKCTSSCTSBPTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644326-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK CANADA INC (CA) | 2016-11-02 | — | — | EP | claimed |
| US-7405229-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-07-29 | — | — | US | claimed |
| US-20070167635-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2007-07-19 | — | — | US | claimed |
| EP-1644326-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK CANADA INC (CA) | 2016-11-02 | — | — | EP | disclosed |
| US-7405229-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-07-29 | — | — | US | disclosed |
| US-20070167635-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167635-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSK | CTSK 3/4885CTSS 2/4885CTSB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.